Vorapaxar Sulfate
- CAS No.
- 705260-08-8
- Chemical Name:
- Vorapaxar Sulfate
- Synonyms
- Vorapaxar-d5;Zontivity;Sch 530348;Vorapaxar Sulfate;SCH 530348 sulfate;SCH-530348;SCH530348;vorapaxar impurity A;vorapaxar monosulfate;Vorapaxar Sulfate API;Vorapaxar sulfate salt
- CBNumber:
- CB92545858
- Molecular Formula:
- C29H35FN2O8S
- Molecular Weight:
- 590.66
- MDL Number:
- MFCD16038877
- MOL File:
- 705260-08-8.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| storage temp. | 4°C, away from moisture |
|---|---|
| solubility | DMSO : 125 mg/mL (211.63 mM; Need ultrasonic)| (insoluble) |
| form | Solid |
| color | White to off-white |
| Water Solubility | Water : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) |
| FDA UNII | IN66038E6C |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H320-H335 |
| Precautionary statements | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
Vorapaxar Sulfate price More Price(38)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0002462 | Vorapaxar sulfate 99.81% | 705260-08-8 | 5mg | $97 | 2026-06-04 | Buy |
| ChemScene | CS-0002462 | Vorapaxar sulfate 99.81% | 705260-08-8 | 10mg | $162 | 2026-06-04 | Buy |
| ChemScene | CS-0002462 | Vorapaxar sulfate 99.81% | 705260-08-8 | 25mg | $303 | 2026-06-04 | Buy |
| ChemScene | CS-0002462 | Vorapaxar sulfate 99.81% | 705260-08-8 | 50mg | $487 | 2026-06-04 | Buy |
| ChemScene | CS-0002462 | Vorapaxar sulfate 99.81% | 705260-08-8 | 100mg | $780 | 2026-06-04 | Buy |
Vorapaxar Sulfate Chemical Properties,Uses,Production
Description
Merck Sharp & Dohme successfully obtained approval in the EU in 2014 for vorapaxar sulfate, marketed as Zontivity®. The drug is a first-in-class thrombin receptor (also referred to as a protease-activated or PAR-1) antagonist which, when used in conjunction with antiplatelet therapy, has been shown to reduce the chance of myocardial infarction and stroke, particularly in patients with a history of cardiac events. Antagonism of PAR-1 allows for thrombin-mediated fibrin deposition while blocking thrombinmediated platelet activation.
Uses
SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis. acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.
Definition
ChEBI: An organic sulfate salt obtained by combining vorapaxar with one molar equivalent of sulfuric acid. A protease-activated receptor-1 antagonist used for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (M ) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation.
Synthesis
Although a variety of papers and patents describe the synthesis
of vorapaxar sulfate (XXXVII), a combination of two patents
describe the largest-scale synthesis reported in the literature. Retrosynthetically, the drug can be
divided into olefination partners 306 and 305. Lactone 305
is further derived from synthons 300 and 299, which are readily
prepared from commercially available starting materials. Dienyl
acid 300 was constructed in two steps starting from commercial
vinyl bromide 307, which first undergoes a Heck reaction with
methacrylate (308) followed by saponification of the ester to afford
the desired acid 300 in 71% over two steps.
The synthesis of alcohol 299 begins with tetrahydropyranyl
(THP) protection of enantioenriched alcohol 295 to afford butyne
297 . Lithiation of this system followed by trapping
with (benzyloxy)chloroformate and Dowex work-up to remove
the protective functionality provided acetyl ester 298. Hydrogenation
of the alkyne with Lindlarˉs catalyst delivered cis-allylic alcohol
299 in 93% yield. Acid 300 was then esterified with alcohol
299 by way of a 1,3-dicyclohexylcarbodiimide (DCC) coupling
and, upon heating in refluxing xylenes, an intramolecular Diels¨C
Alder reaction occurred. Subsequent subjection to DBU secured
the tricyclic system 301 in 38% over three steps as a single enantiomer.
Diastereoselective hydrogenation reduced the olefin with
concomitant benzyl removal to give key fragment 302. Next, acidic
revelation of the ketone followed by reductive amination with
ammonium formate delivered primary amines 303a/303b as a
mixture of diastereomers. These amines were then converted to
the corresponding carbamates, and resolution by means of recrystallization
yielded 50% of 304 as the desired diastereomer. Acid 304
was treated with oxalyl chloride and the resulting acid chloride
was reduced to aldehyde 305 in 66% overall yield. Finally, deprotonation
of phosphonate ester 306 followed by careful addition of 305 and acidic quench
delivered vorapaxar sulfate (XXXVII) in excellent yield over the
two-step protocol.
The preparation of vorapaxar phosponate ester 306
commenced from commercial sources of 5-(3-fluorophenyl)-2-
methylpyridine (310). Removal of the methyl proton with LDA
followed by quench with diethyl chlorophosphonate resulted in
phosponate ester 306.
Vorapaxar Sulfate Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Boyle Chemical Co., Ltd. | sales@boylechem.com | China | 2915 | 55 | |
| Chemvon Biotechnology Co., Ltd | 021-50790412 | info@chemvon.com | China | 371 | 57 |
| Chembest Research Laboratories Limited | 021-20908456 | sales@BioChemBest.com | China | 5996 | 61 |
| Chemsky (shanghai) International Co.,Ltd | 021-50135380 | shchemsky@sina.com | China | 15350 | 60 |
| Jinan Trio PharmaTech Co., Ltd. | 0531-88811783 | sales@trio-pharmatech.com | China | 1856 | 62 |
| Dalian Meilun Biotech Co., Ltd. | 0411-62910999 13889544652 | sales@meilune.com | China | 4765 | 58 |
| S.Z. PhyStandard Bio-Tech. Co., Ltd. | 0755-83725681-603 | China | 4484 | 50 | |
| Beijing Yisiyan Technology Research Center | 010-56645598 13366904824; | bjkaida@163.com | China | 1596 | 59 |
| Guangzhou Isun Pharmaceutical Co., Ltd | 020-39119399 18927568969 | isunpharm@qq.com | China | 4773 | 55 |
| TargetMol Chemicals Inc. | 021-021-33632979 15002134094 | marketing@targetmol.com | China | 7993 | 58 |
View Lastest Price from Vorapaxar Sulfate manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-09-14 | Vorapaxar Sulfate
705260-08-8
|
1g | More Than 99% | 100kg/Month | BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | ||
 |
2026-07-27 | Vorapaxar sulfate
705260-08-8
|
$32.00-72.00 | 99.99% | 10g | TargetMol Chemicals Inc. | ||
 |
2023-06-26 | Vorapaxar Sulfate
705260-08-8
|
$200.00 | 1kg | 99% | 1000kg/Month | Hebei Mingeng Biotechnology Co., Ltd |
-
- Vorapaxar Sulfate
705260-08-8
- $0.00
- More Than 99%
- BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
-
- Vorapaxar sulfate
705260-08-8
- $32.00-72.00
- 99.99%
- TargetMol Chemicals Inc.
-
- Vorapaxar Sulfate
705260-08-8
- $200.00
- 99%
- Hebei Mingeng Biotechnology Co., Ltd
705260-08-8(Vorapaxar Sulfate)Related Search:
1of4
